SecurityLJPC / La Jolla Pharmaceutical Co.
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Institutional Buyers67
Opened Positions20

Institutional and Fund Ownership - Buyers

Major holders that have opened new positions in LJPC / La Jolla Pharmaceutical Co. include Scopia Capital Management Lp, Artal Group S.A., Rock Springs Capital Management LP, DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main, Millennium Management Llc, J. Goldman & Co LP, Asymmetry Capital Management, L.P., J. Goldman & Co LP, JP Morgan Chase & Co, JP Morgan Chase & Co, Citadel Advisors Llc, Iszo Capital Management Lp, Citadel Advisors Llc, Citadel Advisors Llc, Winton Capital Group Ltd, Silvant Capital Management Llc, Springbok Capital Management, Llc, GV Financial Advisors, Private Capital Group, Llc, and Magee Thomson Investment Partners Llc.

This page shows changes in the ownership structure by listing institutions, funds, and major shareholders that have increased their holdings or opened new positions in the last reporting period. Green rows indicate new positions. Click the link icon to see the full transaction history.

File DateFormInvestor Option Prev Shares Shares Change
(Percent)
Prev Value
(x$1000)
Current Value (x$1000) Change
(Percent)
2018‑05‑15 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 0 33,956 0 1,011
2018‑05‑14 13F-HR ALLIANCEBERNSTEIN L.P. 17,100 112,100 555.56 550 3,338 506.91
2018‑05‑11 13F-HR CITIGROUP INC 18,730 47,406 153.10 603 1,411 134.00
2018‑04‑20 13F-HR JENNISON ASSOCIATES LLC 2,220,482 3,137,062 41.28 71,455 93,422 30.74
2018‑05‑15 13F-HR Rock Springs Capital Management LP 220,000 6,552
2018‑05‑11 13F-HR HAP Trading, LLC Put 0 200,000 0 120
2018‑05‑11 13F-HR HAP Trading, LLC 0 36,636 0 1,091
2018‑05‑15 13F-HR CREDIT SUISSE AG/ 16,855 17,037 1.08 541 507 -6.28
2018‑05‑07 13F-HR Red Cedar Capital, Llc 4,700 5,700 21.28 151 170 12.58
2017‑05‑15 13F-HR ISZO CAPITAL MANAGEMENT LP 30,967 924
2018‑05‑15 13F-HR Tower Research Capital LLC (TRC) 0 12,833 0 382
2018‑05‑15 13F-HR J. Goldman & Co LP Put 82,900 2,469
2018‑05‑14 13F-HR EMORY UNIVERSITY 51,632 77,335 49.78 1,662 2,303 38.57
2018‑05‑09 13F-HR Candriam Luxembourg S.C.A. 269,000 348,000 29.37 8,656 10,364 19.73
2018‑05‑15 13F-HR PERCEPTIVE ADVISORS LLC 3,388,611 4,313,611 27.30 109,046 128,459 17.80
2017‑02‑10 13F-HR BlackRock Institutional Trust Company, N.A. 361,333 361,437 0.03 8,596 6,336 -26.29
2018‑05‑14 13F-HR/A CITADEL ADVISORS LLC 0 29,906 0 891
2018‑05‑15 13F-HR PEAK6 Investments, L.P. 0 5,800 0 173
2018‑05‑14 13F-HR Broadfin Capital, LLC 1,029,866 1,656,720 60.87 33,141 49,337 48.87
2018‑05‑07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 75,298 86,430 14.78 2,424 2,574 6.19
2018‑05‑15 13F-HR BANK OF AMERICA CORP /DE/ 30,248 47,879 58.29 973 1,425 46.45
2018‑05‑14 13F-HR NOMURA ASSET MANAGEMENT CO LTD 0 0 0 0
2018‑05‑21 13F-HR Winton Capital Group Ltd 9,259 276
2018‑05‑11 13F-HR CITADEL ADVISORS LLC Call 31,100 926
2018‑05‑03 13F-HR Trexquant Investment LP 0 26,682 0 795
2018‑05‑11 13F-HR CITADEL ADVISORS LLC 29,906 891
2018‑05‑15 13F-HR BARCLAYS PLC 2,772 3,627 30.84 89 108 21.35
2017‑02‑10 13F-HR BlackRock Investment Management, LLC 55,913 56,235 0.58 1,330 986 -25.86
2018‑04‑26 13F-HR SIMPLEX TRADING, LLC Call 97 165 70.10 7 33 371.43
2018‑05‑15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 155,954 170,842 9.55 5,018 5,087 1.38
2018‑05‑15 13F-HR Bank of New York Mellon Corp 83,754 86,262 2.99 2,695 2,569 -4.68
2017‑04‑21 13F-HR MAGEE THOMSON INVESTMENT PARTNERS LLC 17 1
2018‑05‑11 13F-HR BNP PARIBAS ARBITRAGE, SA 3,619 3,674 1.52 116,459 109,412 -6.05
2018‑05‑15 13F-HR Alyeska Investment Group, L.P. 0 21,075 0 628
2018‑05‑14 13F-HR VIRTUS ETF ADVISERS LLC 14,394 31,173 116.57 463 928 100.43
2018‑02‑09 13F-HR RidgeWorth Capital Management LLC 6,963 20,812 198.89 242 670 176.86
2018‑05‑15 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 0 25,500 0 759
2018‑05‑15 13F-HR UBS Group AG 15,513 97,622 529.29 499 2,907 482.57
2018‑05‑10 13F-HR SPHERA FUNDS MANAGEMENT LTD. 225,000 260,000 15.56 7,241 7,743 6.93
2018‑05‑04 13F-HR Swiss National Bank 29,400 33,100 12.59 946 986 4.23
2018‑05‑10 13F-HR Monashee Investment Management LLC 185,000 2,985 5,509 84.56
2018‑05‑15 13F-HR VANGUARD GROUP INC 802,012 927,869 15.69 25,808 27,631 7.06
2017‑08‑08 13F-HR Airain ltd 0 17,519 0 522
2018‑05‑15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 38,100 58,200 52.76 1,226 1,733 41.35
2018‑04‑26 13F-HR SIMPLEX TRADING, LLC Put 264 570 115.91 54 136 151.85
2018‑05‑14 13F-HR RTW INVESTMENTS, LLC 1,063,170 1,122,540 5.58 34,213 33,429 -2.29
2018‑05‑14 13F-HR FMR LLC / Fidelity 3,321,786 3,602,698 8.46 106,895 107,288 0.37
2018‑05‑15 13F-HR Kazazian Asset Management, LLC 12,263 15,516 26.53 395 462 16.96
2018‑05‑15 13F-HR SCOPIA CAPITAL MANAGEMENT LP 578,145 17,217
2018‑04‑25 13F-HR PICTET ASSET MANAGEMENT LTD 906,456 1,036,941 14.40 29,170 30,880 5.86
2018‑05‑14 13F-HR TOCQUEVILLE ASSET MANAGEMENT L.P. 0 7,850 0 234
2018‑05‑15 13F-HR WOLVERINE TRADING, LLC Call 0 6,800 0 203
2018‑05‑15 13F-HR PEAK6 Investments, L.P. Put 0 15,000 0 447
2018‑05‑18 13F-HR/A ROYAL BANK OF CANADA 310 3,102 900.65 10 93 830.00
2018‑05‑15 13F-HR DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 109,261 3,254
2018‑05‑10 13F-HR JP Morgan Chase & Co Put 54,000 1,608
2018‑05‑15 13F-HR WOLVERINE TRADING, LLC 10,799 11,338 4.99 348 338 -2.87
2018‑05‑15 13F-HR BARCLAYS PLC Call 0 35,700 0 1,063
2018‑05‑10 13F-HR JP Morgan Chase & Co 3,772 137,144 3,535.84 121 4,084 3,275.21
2018‑05‑04 13F-HR PRUDENTIAL FINANCIAL INC 186,889 203,089 8.67 6,064 6,048 -0.26
2018‑05‑15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 0 16,922 0 504
2017‑02‑10 13F-HR BlackRock Fund Advisors 387,615 446,293 15.14 9,221 7,824 -15.15
2018‑05‑10 13F-HR JP Morgan Chase & Co Call 54,000 1,608
2018‑05‑15 13F-HR MILLENNIUM MANAGEMENT LLC Put 100,000 2,978
2018‑05‑15 13F-HR SECTORAL ASSET MANAGEMENT INC 854,301 1,128,219 32.06 27,491 33,598 22.21
2017‑08‑18 13F-HR WFG Advisors, LP 0 60 0 2
2018‑05‑08 13F-HR Asymmetry Capital Management, L.P. 55,864 1,664
2018‑05‑15 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC Put 5,000 149
2018‑05‑14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 15,604 16,467 5.53 502 490 -2.39
2018‑05‑14 13F-HR ASCEND CAPITAL, LLC 189,041 251,644 33.12 6,084 7,494 23.18
2018‑05‑15 13F-HR STATE STREET CORP 856,186 1,480,288 72.89 27,551 44,086 60.02
2018‑05‑03 13F-HR SG Americas Securities, LLC 0 4,513 0 134
2018‑05‑15 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC Call 0 2,200 0 66
2018‑05‑15 13F-HR TANG CAPITAL MANAGEMENT LLC 3,440,419 4,138,893 20.30 110,713 123,256 11.33
2018‑05‑10 13F-HR Artal Group S.A. 300,000 8,934
2018‑05‑09 13F-HR Silvant Capital Management Llc 6,353 189
2018‑05‑16 13F-HR Private Capital Group, Llc 36 1
2018‑05‑15 13F-HR J. Goldman & Co LP 55,300 1,647
2017‑02‑10 13F-HR BlackRock Group LTD 3,732 4,299 15.19 89 76 -14.61
2018‑05‑11 13F-HR CITADEL ADVISORS LLC Put 18,000 536
2018‑05‑15 13F-HR GV Financial Advisors 1,125 34

Related Articles

HIMX: Himax Technologies Analysis and Research Report

7h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

CUSIP: 503459604